Published online Oct 28, 2020. doi: 10.5495/wjcid.v10.i4.55
Peer-review started: June 11, 2020
First decision: July 4, 2020
Revised: August 2, 2020
Accepted: September 18, 2020
Article in press: September 18, 2020
Published online: October 28, 2020
Processing time: 138 Days and 18.7 Hours
The current corona-2 pandemic has stimulated wide research for hydroxychloroquine (Quine) therapy and lately, prophylaxis. To optimize prophylaxis proper methods of use are explained. The focus is on tools of assessment and robust comparison; defining infection objectively; loading and maintenance dose designing based on pharmaco-viro-kinetics; confirming Quine threshold-levels and its sufficiency; and Quine side-effects vigilance/ amelioration. Attention to statistics to study valid endpoints of goals in appropriately-sized population is essential. Mass interactive quine dose auto designer software is built to simplify, optimize and help collaboration of complex Quine dosing system. A similar chloroquine software can be built.
Core Tip: Quine's role in corona-2 pandemic prophylaxis can be assured via designing correct loading doses (LD)/ maintenance doses (MD), therapy duration, and volumetric absorptive microsampling (VAMS) concentrations, assuring human IC50 and Liver and Heart safety thresholds of TCL10 and TCH10. Surely, good care will translate VeroE6 Viro-kinetics into human Viro-kinetics and help human-tailored dosing; not misguided by improper models, malaria, or rheumatology doses. Mass interactive quine dose auto designer (MIQDAD), viral count, and VAMS test help initial Quine LD/MD designing and human-tailored LD/MD dosing.